SEC
SlamSEC
SearchBrowseEarnings

LIGAND PHARMACEUTICALS INC

Nasdaq:LGNDOTC:LGNDZOTC:LGNXZOTC:LGNYZOTC:LGNZZ
Pharmaceutical Preparations·SAN DIEGO, CA
OverviewAll FilingsSum FinCreditInsidersGovernance
OverviewAll FilingsSum FinCreditInsidersGovernance

All Filings(1000 total)

TypeDateAccessionPeriodSize
4
Mar 13, 2026
0002001011-26-000026PRIMARY DOCUMENT
Mar 11, 2026
8.2 KB
144
Mar 11, 2026
0001950047-26-002496
—
6.7 KB
4
Mar 6, 2026
0002001011-26-000024PRIMARY DOCUMENT
Mar 4, 2026
26.6 KB
4
Mar 6, 2026
0002001011-26-000023PRIMARY DOCUMENT
Mar 4, 2026
30.9 KB
144
Mar 6, 2026
0001950047-26-002309
—
4.6 KB
4
Mar 5, 2026
0001104659-26-023943OWNERSHIP DOCUMENT
Mar 3, 2026
9.4 KB
4
Mar 4, 2026
0002001011-26-000018PRIMARY DOCUMENT
Mar 2, 2026
13.9 KB
144
Mar 4, 2026
0001950047-26-002204
—
4.9 KB
144
Mar 4, 2026
0001950047-26-002183
—
5.5 KB
144
Mar 3, 2026
0001950047-26-002083
—
4.6 KB
S-3ASR
Feb 27, 2026
0001193125-26-083241S-3ASR
—
1.1 MB
10-K
Feb 27, 2026
0000886163-26-00000610-K
Dec 31, 2025
18.7 MB
8-K
Feb 26, 2026
0000886163-26-0000038-K
Feb 26, 2026
419.3 KB
4
Feb 18, 2026
0002001011-26-000013PRIMARY DOCUMENT
Feb 14, 2026
13.1 KB
4
Feb 18, 2026
0002001011-26-000012PRIMARY DOCUMENT
Feb 14, 2026
13.2 KB
4
Feb 18, 2026
0002001011-26-000011PRIMARY DOCUMENT
Feb 14, 2026
13.1 KB
4
Feb 4, 2026
0002001011-26-000007PRIMARY DOCUMENT
Feb 2, 2026
10.5 KB
144
Feb 2, 2026
0001969223-26-000093
—
6.2 KB
4
Jan 6, 2026
0002001011-26-000004PRIMARY DOCUMENT
Jan 2, 2026
11.6 KB
4
Jan 6, 2026
0002001011-26-000003PRIMARY DOCUMENT
Dec 31, 2025
4.6 KB
144
Jan 2, 2026
0001969223-26-000006
—
5.5 KB
4
Dec 19, 2025
0001193125-25-3268914
Dec 17, 2025
9.6 KB
4
Dec 18, 2025
0002001011-25-000127PRIMARY DOCUMENT
Dec 16, 2025
20.8 KB
8-K
Dec 18, 2025
0001193125-25-3248308-K
Dec 18, 2025
134.6 KB
4
Dec 16, 2025
0002001011-25-000125PRIMARY DOCUMENT
Dec 12, 2025
4.4 KB
25 filings shown

Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas.

CEO
Davis Todd C
CFO
Espinoza Octavio